Aeluma, Inc. — Form 10-Q Summary
Reporting period: The fiscal quarter and six months ended December 31, 2023 (quarter ended December 31; the filing compares with the corresponding 2022 periods). Aeluma develops compound-semiconductor optoelectronic devices, including infrared sensors, and remains in the research and development stage.
Financial performance
| Metric | Three months ended Dec. 31, 2023 | Six months ended Dec. 31, 2023 |
|---|---|---|
| Revenue | $262,992 | $295,392 |
| Cost of revenue | $136,767 | $151,906 |
| Operating expenses | $1,391,791 | $2,906,902 |
| Operating loss | $(1,128,799) | $(2,611,510) |
| Net loss | $(1,128,520) | $(2,610,829) |
| Basic and diluted loss per share | $(0.09) | $(0.21) |
Six-month revenue comprised $262,992 from government contracts and $32,400 from product sampling sales. Approximate gross margin was 48% for both the quarter and six-month period, calculated from reported revenue and cost of revenue. No income tax expense was reported.
At December 31, 2023, cash and cash equivalents were $2.42 million, working capital was $2.35 million, and total liabilities were $1.46 million. Operating cash outflow for the six months was $2.48 million; investing cash outflow was $164,290. The company reported no borrowings in the presented balance sheet; operating lease liabilities totaled $1.13 million, including $124,145 current. Accumulated deficit was $11.67 million.
Changes versus prior comparable period
- Revenue increased from zero in the prior-year quarter and six-month period. Management said the company was pre-revenue in the prior-year six-month period.
- Six-month net loss was essentially unchanged year over year: $2.61 million versus $2.61 million. Operating expenses increased $185,321, while other income declined $110,310, principally because the facility sublease ended in March 2023.
- Cash fell $2.65 million from June 30, 2023. Operating cash use increased from $2.00 million in the prior-year six-month period to $2.48 million.
- The company repurchased 649,570 unvested shares from a former executive for $4,001. Shares outstanding were 12,167,930 at December 31, 2023.
Outlook, risks and notable items
- Going concern: The filing states that substantial additional funding is needed, losses are expected to continue, and current cash is insufficient to complete the business plan. These conditions raise substantial doubt about the company’s ability to continue as a going concern. Management’s plans include raising capital or obtaining financing, controlling expenses, and securing material sales or research contracts; there were no formal agreements for these plans as of the report date.
- Contract revenue: The company reported $435,463 of remaining government-contract performance obligations, expected to be recognized within 12 months. It also disclosed two government contract awards totaling $477,069; the filing does not clearly reconcile the award total with the remaining-obligations figure.
- Controls: Management concluded disclosure controls and procedures were not effective at December 31, 2023, citing insufficient finance-department staffing and inadequate precision, evidence, or timeliness in review controls. No material changes in internal control over financial reporting were reported during the six months.
- Other items: The company is developing manufacturing and product capabilities and continues to rely on external financing. The filing notes lingering supply-chain challenges but no significant COVID-19 impact during the period. Management reported no known legal proceedings expected to have a material adverse effect.
Investor verification priorities
- Assess funding needs, cash use, and the ability to raise capital on acceptable terms given the stated going-concern uncertainty.
- Track conversion of government-contract awards and the $435,463 remaining performance obligations into recognized revenue and cash receipts.
- Monitor operating expenses, product sales, margins, and progress toward sustained commercial revenue.
- Check whether finance staffing and review-control deficiencies are remediated.
- Review lease commitments and potential dilution from outstanding options and warrants.